Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving

CL Haass-Koffler1,2, EG Aoun3, RM Swift4,5, SM de la Monte6, GA Kenna4 and L Leggio1,2

Increasing evidence supports the role of appetite-regulating pathways, including ghrelin and leptin, in alcoholism. This study tested the hypothesis that intravenous exogenous ghrelin administration acutely decreases endogenous serum leptin levels, and that changes in leptin levels negatively correlate with alcohol craving. This was a double-blind, placebo-controlled human laboratory study. Non-treatment-seeking, alcohol-dependent, heavy drinkers (n = 45) were randomized to receive intravenous ghrelin or placebo, followed by a cue-reactivity procedure, during which participants were exposed to neutral (juice) and alcohol trial cues. There was a main effect for intravenous ghrelin administration, compared with placebo, in reducing serum leptin levels (P < 0.01). Post hoc analysis showed significant differences in serum leptin levels at the alcohol trial (P < 0.05) that persisted at the end of the experiment (P < 0.05). By contrast, there were no significant differences in serum leptin levels at the juice trial (P = not significant (NS)). The change of serum leptin level at the alcohol trial correlated with the increase in alcohol urge (P < 0.05), whereas urge to drink juice was not correlated with the leptin change at the juice trial (P = NS). These findings provide preliminary evidence of ghrelin-leptin cross-talk in alcoholic individuals and suggest that their relationship may have a role in alcohol craving.

Translational Psychiatry (2015) 5, e646; doi:10.1038/tp.2015.140; published online 29 September 2015

INTRODUCTION
Alcohol dependence (AD) is a leading cause of preventable morbidity and mortality worldwide.1,2 Medications currently approved by the Food and Drug Administration to treat AD exhibit limited efficacy.3 As such, identifying neurobiological pathways involved in the development and maintenance of AD may lead to novel pharmacological targets for AD treatment.4

Increasing evidence supports the role of appetite-regulating pathways in addiction.5,6 In particular, ghrelin, a 28-aa (amino acid) residue peptide produced primarily by the stomach, has a key role in increasing appetite, food intake and reward.7 Ghrelin was also found to have a role in alcohol reward, alcohol consumption and other alcohol-seeking behaviors in rodents (for review, see refs 5,8). A longitudinal clinical study revealed a positive correlation between blood ghrelin levels and both alcohol craving and risk of relapse in AD patients.9 More recent clinical research indicated that intravenous administration of exogenous ghrelin acutely increased cue-induced alcohol craving in heavy-drinking AD individuals.10

Leptin is a feeding-related 146-aa peptide produced by adipose tissue that may also have a role in AD. Serum leptin levels were found to be elevated in AD individuals and associated with increased craving for alcohol.11,12 Moreover, in AD patients, treatment with naltrexone and/or acamprosate was associated with lower leptin levels, suggesting leptin may serve as a possible biomarker for medication response.13 Two other peripherally secreted adipose hormones are resistin, a 108-aa protein produced in the stromal vascular fraction of adipose tissue and peripheral blood monocytes14 and visfatin, a 491-aa peptide produced by the visceral adipose tissue.15 Leptin, resistin and visfatin may have important roles in metabolism and energy balance in several endocrine disorders (for review, see ref. 16). Although the exact physiologic function of resistin in humans is still unknown,17 one study reported alteration of resistin levels during alcohol withdrawal in AD individuals.18 No clinical findings on visfatin in AD have been reported.

Leptin and ghrelin have inverse appetite effects; leptin decreases appetite, food intake and reward, whereas ghrelin exhibits opposite roles on these behaviors.19,20 An interaction (‘cross-talk’) between ghrelin and leptin in regulating appetite and reward signaling has been described.20 Although both peptides act as afferent signals to the hypothalamus,21 leptin and ghrelin receptors are also expressed in motivation reward brain regions linked to food-related behaviors such as ventral tegmental area and substantia nigra that signal via dopaminergic neurons to cortical and limbic region involved in motivational response to both food22,23 and drugs.24,25 Consistent with the opposite orexigenic and anorectic effects of ghrelin and leptin, electrophysiological data have shown that treatment of neurons with leptin or ghrelin revealed antagonism between the effect of these two hormones on the neural activity of the arcuate nucleus,26 a hypothalamic area with a leaky blood–brain barrier that may favor larger molecules trafficking.26

The present study was aimed at investigating the relationship between ghrelin and leptin in alcohol craving by analyzing these
Serum levels in a human laboratory placebo-controlled study with heavy-drinking AD individuals receiving intravenous ghrelin.\textsuperscript{10} Consistent with the opposite physiological roles of ghrelin vs leptin,\textsuperscript{19,20} our hypothesis was that intravenous exogenous ghrelin administration acutely decreases endogenous serum leptin levels, and that changes in leptin levels negatively correlate with alcohol craving. Finally, the potential effects of intravenous ghrelin in resistin and visfatin levels were explored.

**MATERIALS AND METHODS**

**Setting**

This study was conducted at the Brown University Center for Alcohol and Addiction Studies, Providence, RI, USA. The study was approved by the Brown University Institutional Review Board. The use of synthetic human ghrelin was approved under the Food and Drug Administration Investigational New Drug (IND #109,242). Participants signed an informed consent before participation.

**Summary of the parent study**

The parent study\textsuperscript{10} was a three-group between-subject, double-blind, placebo-controlled randomized proof-of-concept human laboratory study with 45 non-treatment-seeking heavy-drinking AD individuals (ClinicalTrials.gov: NCT01100085). In brief, individuals were enrolled accordingly to the DSM-IV diagnosis of alcohol dependence; heavy drinking was defined as consuming on average \( \geq 4 \) standard drinks per day for women or \( \geq 5 \) standard drinks per day for men, during the 90-day period before screening, as assessed by the Timeline Follow-Back. A breath alcohol concentration of 0.00 and being fasting was required on the day of the human laboratory experiment. An intravenous cannula was placed, and a fixed light breakfast of \( \sim 700 \text{kJ} \) (62% carbohydrate, 13% protein and 25% fat) was served. Participants then received an \( \sim 10 \)-min administration of intravenous ghrelin at a dose of either \( 3 \) or \( 1 \) \( \mu \text{kg}^{-1} \), \( 1 \) or \( 0 \) \( \mu \text{kg}^{-1} \) (placebo). Following the intravenous infusion, participants were exposed to a neutral (juice) cues trial and an alcohol cues trial. At the end of each trial, urge was assessed by using either an Alcohol Visual Analogue Scale or a Likert-type scale.\textsuperscript{27} Then, another neutral and alcohol cues trial was conducted. Blood samples for hormones were collected at six time points during the experiment, that is, at baseline (before the infusion), immediately following each of the four trials, and finally before discharge (48 min following the infusion).

The main findings of the parent study were a significant effect of ghrelin \( 3 \times 10^{-3} \) vs placebo on alcohol craving \((P < 0.05)\) but not on juice craving \((P = 0.57)\). A significant positive correlation between post-infusion blood ghrelin concentration and the increase in urge to drink alcohol was also noted \((P < 0.05)\).\textsuperscript{10}

**Blood samples analysis**

The intravenous ghrelin/placebo infusion was a 10-min bolus that took place from \( -10 \text{ min} \) to 0 min. Blood sample time points were at baseline \(( -15 \text{ min})\), after the first juice trial \((+6 \text{ min})\), the first alcohol trial \((+17 \text{ min})\), the second juice trial \((+23 \text{ min})\), the second alcohol trial \((+29 \text{ min})\) and post experiment \((+48 \text{ min})\). Blood samples were centrifuged and stored at \( -80^\circ \text{C} \).

Leptin, resistin and visfatin levels were determined using a fluorescent bead-based Bio-Plex assay (Bio-Rad, Hercules, CA, USA). Results were expressed as pg ml\(^{-1}\).

**Data analytic strategy**

Considering there were no significant differences between the two ghrelin doses in the main study,\textsuperscript{10} for this analysis we collapsed the two intravenous ghrelin groups \((1 \times 10^{-3} \text{ vs } 3 \times 10^{-3})\) and compared them with placebo.

Analysis was limited to blood samples collected at baseline \(( -15 \text{ min})\), during the second juice and alcohol trials \((+23 \text{ and } +29 \text{ min})\) and before discharge \((+48 \text{ min})\). In fact, ghrelin’s pharmacokinetics profile predicts that its levels would be positive and relatively constant during this time period, as ghrelin maximum concentration is reached \( \sim 10 \text{ min} \) following intravenous administration and its half-life \((t_{1/2})\) can be as long as 47 min for a bolus injection.\textsuperscript{29} The previous blood samples were collected around \( t_{\text{max}} \) \((+6 \text{ and } +17 \text{ min}; \text{first juice and alcohol trial, respectively})\), and as such, would have been too early to detect a possible effect of intravenous ghrelin administration on the endogenous levels of the adipose hormones here analyzed. In addition, previous human laboratory studies using cue-reactivity procedures indicate that elicited craving response is stronger when cue exposure is repeated \( (\text{that is, during the second trial})\).\textsuperscript{26} Of note, in the parent study, elicited craving was more pronounced during the second trial.\textsuperscript{10}

Serum hormones levels were normalized to reduce individual and gender-related\textsuperscript{31} variability, evaluated as change from baseline\textsuperscript{33} and expressed as means and standard errors \((\text{s.e.m.})\). Distributional characteristics of outcome measures were examined to evaluate similarity to the normal distribution. Although hormones levels had a slight larger skewness and kurtosis, outliers were taken into account as previously suggested.\textsuperscript{14} Consistent with previous leptin-related literature in the alcoholism field,\textsuperscript{11,12} hormone/body mass index \((\text{BMI})\) ratio was used as the primary way to express hormones levels. In addition, hormone serum levels were analyzed using BMI as covariate in the model.\textsuperscript{15,16} BMI was taken into account considering that all hormones investigated here are secreted by adipocytes and that BMI is a measure of adipocyte secreting activity.\textsuperscript{16}

The statistical method used was repeated measures analysis of covariance, followed by an unpaired \( t \)-test to detect the differences in serum hormone levels among groups at specific time points. All pairwise comparisons were covariate adjusted and corrected with a Bonferroni correction \( (P_{\text{corrected}})\). The percent change from baseline was used to evaluate potential correlations with craving scores \((\text{Alcohol Visual Analogue Scale or Juice Visual Analogue Scale})\) via regression analysis using Pearson’s correlation coefficient; this latter analysis was only conducted with the hormones for which a significant intravenous ghrelin effect was detected. All statistical tests were two-sided, and statistical significance was accepted if a \( P \)-value \( < 0.05 \) was obtained. SPSS \((5.22; \text{Armonk, NY, USA})\) was used to conduct the analysis and GraphPad Prism \((5.5)\) was used to generate figures \((\text{La Jolla, CA, USA})\).

**RESULTS**

**Description of the sample**

Out of the 45 participants in the parent study, data for this analysis were available for 43 subjects. Demographics and baseline characteristics are outlined in the parent study.\textsuperscript{10} There were no significant differences in the demographics and baseline characteristics, including basal ghrelin levels between groups in the main sample of the parent study and the sample of this analysis. Demographic and baseline characteristics are outlined in the parent study and the sample of this analysis.

**Changes in endogenous leptin level after intravenous infusion**

Serum leptin values in the two groups \((\text{intravenous ghrelin vs placebo})\) were normalized and evaluated as change from baseline. There was a main effect for intravenous ghrelin administration in changing serum leptin levels expressed as leptin/BMI ratio \((F_{1,38} = 8.249, P = 0.007)\). Post hoc analysis revealed significant differences in reducing leptin levels at the alcohol trial \((t_{38} = 2.703, P_{\text{corrected}} = 0.031)\) that persisted at the end of the experiment \((t_{38} = 2.720, P_{\text{corrected}} = 0.029); \text{Figure 2}\).

These results were confirmed when leptin was expressed as serum level with the BMI used as covariate. Specifically, there was a main effect for intravenous ghrelin administration in reducing serum leptin levels \((F_{1,38} = 7.442, P = 0.010)\). Post hoc analysis showed a trend toward a significant difference in reducing leptin levels at the alcohol trial \((t_{38} = 2.468, P_{\text{corrected}} = 0.055)\) that became significant at the end of the experiment \((t_{38} = 2.827, P_{\text{corrected}} = 0.022)\).

By contrast, no significant differences in leptin levels were noted during the juice trial using either leptin/BMI ratio \((\text{Figure 2})\) or serum leptin with BMI as covariate \((P = 0.58)\). Finally, there was no
Consistent with our hypotheses, the main findings of this analysis were that intravenous ghrelin administration significantly decreased serum leptin levels, and ghrelin-induced changes in leptin levels significantly negatively correlated with increased alcohol craving in AD heavy drinkers. We believe this is the first study in which the effects of exogenous intravenous ghrelin administration on endogenous serum leptin levels were assessed in the context of alcohol craving studied in AD individuals. This study provides preliminary evidence supporting a possible ghrelin and leptin relationship (‘cross-talk’) in AD individuals and suggesting that their interaction may have a role in alcohol craving. These results hold important clinical value because craving may be associated with relapse and has been proposed as a clinically relevant endophenotype able to predict alcohol-related outcomes.34 Notably, cue reactivity has demonstrated utility in eliciting urge to drink in AD individuals29 and medications that reduce alcohol consumption also reduce alcohol craving in cue reactivity human laboratory studies.35

Our parent study10 showed that intravenous ghrelin administration resulted in an acute increase in cue-induced urge to drink alcohol; during the experiment, there was also a significant positive correlation between the post-infusion serum ghrelin levels and the increase in urge to drink alcohol. The findings of the present study are consistent with those of the parent study, and also add important information. While the significant positive correlation between post-infusion blood ghrelin levels and the ghrelin-induced increase in urge to drink alcohol reported in the parent study was expected, here we report that a different hormone, leptin, significantly decreased after intravenous ghrelin infusion and its decrease significantly correlated with the change

Figure 1. Relationship between baseline adipose hormones levels and body mass index (BMI). There was a trend toward significant positive correlation between baseline serum (a) leptin (dark blue) levels and BMI ($r_{41} = 0.265$; $P = 0.094$); (b) resistin (green) and (c) visfatin (yellow) levels did not correlate with BMI ($P = NS$). NS, not significant.

Figure 2. Changes in endogenous serum leptin levels expressed as leptin/BMI ratio after intravenous (i.v.) infusion of exogenous ghrelin (light blue) vs placebo (dark blue). The i.v. ghrelin/placebo infusion was a 10-min bolus that took place from −10 min to 0 min. Leptin time points are at baseline (−15 min), at the juice trial (+23 min), at the alcohol trial (+29 min) and post experiment (+48 min). There was a main effect for i.v. ghrelin administration on serum leptin levels ($F_{(1,36)} = 8.249$, $P = 0.007$). Post hoc analysis revealed significant differences in leptin levels at the alcohol trial ($t_{36} = 2.703$, $P_{corrected} = 0.031$) that persisted at the end of the experiment ($t_{36} = 2.720$, $P_{corrected} = 0.029$). No significant differences in leptin levels ($P = NS$) were found during the juice trial ($P = NS$). BMI, body mass index; NS, not significant.
in urge to drink alcohol. As such, leptin may represent a biomarker of ghrelin’s effects on alcohol craving in AD individuals. This is relevant, as leptin acts centrally via a negative feedback loop regulating body weight and counteracting ghrelin response. Three additional observations provide support suggesting a possible specific role of leptin as a pharmacodynamic biomarker of ghrelin’s effects in the urge to drink alcohol: (1) the correlation between ghrelin-induced changes in leptin and craving was specific for the urge to drink alcohol, as similar results were not found for the urge to drink juice; (2) the correlation was specific for leptin, as no similar results were found for resistin or visfatin; and (3) although this study did find an effect of intravenous ghrelin on leptin levels in a population of AD patients, it is important to note that in a previous small study with healthy controls, intravenous ghrelin did not change leptin levels. It is possible to speculate that ghrelin’s effects on alcohol craving might be mediated, at least in part, via its effects in specifically reducing leptin levels, which in turn may affect alcohol-seeking behaviors or that leptin may have a protective effect, at least under some conditions, on alcohol craving and drinking. Although this study does not allow us to directly test this hypothesis, we note that putative protective effects of leptin have been reported, as increased leptin serum levels facilitate learning and memory performance in preclinical studies, and have a neuroprotective role in ischemic brain injury. Translational studies, however, are needed to fully address the possible cross-talk between ghrelin and leptin in alcohol craving and drinking.

The positive correlation between serum ghrelin levels and craving (parent study) and the negative correlation between serum leptin levels and craving (present study), together, are consistent with the opposite physiological effects of these two hormones, as well as with the observation that intracerebral administration of ghrelin reversed the effects of leptin in rodents. In addition, our findings are consistent with a recent study where, after alcohol abstinence, AD patients had opposite changes in the endogenous levels of these two peptides, that is, elevated ghrelin and reduced leptin levels.

Some studies suggest a role of leptin itself in alcohol craving, withdrawal-induced craving, including as a possible biomarker to assess medication response in AD individuals. However, while our findings indicate a negative correlation between leptin and craving, others reported a positive correlation. This inconsistency may be owing to several factors, for example, differences in the nutritional status of the subjects across studies, different fasting conditions, potential differences in alcohol drinking and severity of dependence, among the others. The most important difference, however, is that in the study by Kiefer et al., leptin was measured in a placebo-controlled study testing naltrexone and acamprosate, whereas here we studied leptin in a placebo-controlled study testing intravenous ghrelin. In that regard, the present study addresses primarily the potential ghrelin–leptin link in alcohol craving, rather than a role of leptin itself in craving.

From a neurobiological perspective, leptin receptors are expressed in the brain in the satiety centers of the hypothalamus and peripherally in the adipocytes indicating the autocrine and paracrine role of leptin in energy balance (for review, see ref. 45). In the brain, they are also co-expressed with ghrelin receptors mostly in the hypothalamus, and less extent in the other parts of the brain. Interestingly, at the peripheral level, ghrelin directly enhances in vitro adipocyte leptin release, and in vivo the expression of ghrelin receptors increases with adipogenesis. Taken together, these findings may support the possibility of ‘adiposity signals’ that communicate directly to the brain, where ghrelin orexigenic effects antagonize leptin action.

Fat storage has been identified as the most important variable that determines serum leptin levels and the positive relationship between leptin and BMI found in our sample is consistent with what previously described. The lack of similar relationship between BMI and either resistin or visfatin is also consistent with previous literature. In fact, the lack of correlation between resistin and human adiposity, weight and BMI has been already reported (for review, see ref. 17), probably owing to the low resistin messenger RNA expression in human adipocytes compared to rodents. Similarly, even if secreted by adipocytes, visfatin is highly expressed in lean individuals. Although the different relationship with BMI shown by leptin vs resistin or visfatin is in line with the previous published reports, this study allowed us for controlling very carefully for adiposity and BMI as potentially confounders. In fact, the positive findings on leptin were similar when leptin was expressed as either leptin/BMI ratio or leptin levels with BMI as covariate in the model. In addition, ghrelin infusion dose was fixed by weight, rather than using a fixed bolus dose as in the other studies (for review, see ref. 55), thus ensuring that the changes in endogenous leptin levels, driven by exogenous intravenous ghrelin, were controlled by body fat mass. Finally, the effect of intravenous ghrelin infusion was selective for leptin only and evident at the alcohol trial.

This research has a number of strengths, in fact this study was the first to study leptin signaling after an intravenous ghrelin challenge in AD individuals; (b) included a well-validated procedure (that is, cue reactivity); (c) the leptin–ghrelin relationship was investigated in a strict and well-controlled environment, thus allowing us to measure in real time cue-elicited craving and drinking.

Figure 3. Relationship between serum leptin levels expressed as leptin/BMI ratio after intravenous (i.v.) infusion of exogenous ghrelin (light blue) vs placebo (dark blue) and urge to drink alcohol or juice, measured by the Alcohol Visual Analogue Scale (A-VAS) and the Juice Visual Analogue Scale (J-VAS), respectively. (a) Leptin changes were significantly and negatively correlated with the increase in alcohol urge ($r_{40} = -0.342, P = 0.031$) during the alcohol trial (+29 min). (b) but not during the juice trial ($P = NS$). BMI, body mass index; NS, not significant.
control carefully for several possible confounders (for example, recent alcohol and food intake); (d) as mentioned before, intravenous ghrelin dose was calculated on the basis of weight, an important factor for an analysis like this focused on the ghrelin's effects on adipose hormones; (e) normalization of serum leptin at baseline and the percent change from baseline allowed us for accounting for individual variations in circulating leptin levels, including sex-related differences; and (f) the consistency of intravenous ghrelin effect on leptin levels was shown using two separate computational methods. Limitations of the study include: (a) the small sample; (b) the short duration of intravenous ghrelin administration; and (c) the fact that obviously this study does not answer the complementary question of how endogenous ghrelin may vary in AD individuals after an acute exogenous leptin challenge. It is also important to note that other gut-brain peptides regulating appetitive hormones also have a role in alcoholism (for review, see ref. 56), but were not included in this analysis. An additional consideration is that juice and alcohol cues were presented in a fixed order, which may be seen as a limitation. However, the use of a fixed order was done to allow for the most conservative assessment of alcohol cue reactivity as previous studies reported a general lowering of cue reactivity to any stimulus presented second.

In conclusion, the present study provides preliminary evidence of a ghrelin–leptin cross-talk in AD individuals and that their interaction may have a role in alcohol craving. Future translational research is needed to shed light on the potential role of the interaction of these two pathways in alcohol craving and drinking.

CONFLICT OF INTEREST
RMS has received travel and honorarium from D&A Pharma, Lundbeck and consultant fees from CT Laboratories. GAK has received consultant fees from CT Laboratories. The remaining authors declare no conflict of interest.

ACKNOWLEDGMENTS
We acknowledge the technical support from Samuel Frichione and the nursing support from Tamara Sequeira and Julia Nadeau at the Brown University Center for Alcohol and Addiction Studies; and the technical support from Valene Zabalza and Ming Tong at the Rhode Island Hospital and Chetram Deochand and Rosa Yu at the Brown University. The current work of LL is supported by the NIAAA Division of Intramural Clinical and Biological Research and the Intramural Research Program of the National Institute on Drug Abuse. The work of CLH-K is supported by an NIAAA Intramural Clinical and Biological Research and the Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), Grant #R21-AA019709, awarded to LL while he was at the Brown University.

REFERENCES
1 Hingson R, Rehm J. Measuring the burden: alcohol’s evolving impact. Alcohol Res 2013; 35: 122–127.
2 Rehm J, Hingson R. Measuring the burden: alcohol’s evolving impact on individuals, families, and society. Alcohol Res 2013; 35: 117–118.
3 Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014; 311: 1889–1900.
4 Edwards S, Kenna GA, Mora RM, Leggio L. Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des 2011; 17: 1323–1332.
5 Engel JA, Jerlhag E. Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy. CNS Drugs 2014; 28: 875–886.
6 Leggio L, Addolorato G, Cippitelli A, Jerlhag E, Kampov-Polevoy AB, Swift RM. Role of feeding-related pathways in alcohol dependence: a focus on sweet preference, NPY, and ghrelin. Alcohol Clin Exp Res 2011; 35: 194–202.
7 Skibicka KP, Dickson SL. Enteroidrogenic hormones—central effects on behavior. Curr Opin Pharmacol 2013; 13: 977–982.
8 Leggio L. Role of the ghrelin system in alcoholism: acting on the growth hormone secretagogue receptor to treat alcohol-related diseases. Drug News Perspect 2010; 23: 157–166.
9 Leggio L, Ferrulli A, Cardone S, Nesic A, Miceli A, Malandrinio N et al. Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addict Biol 2012; 17: 452–464.
10 Leggio L, Zywiak WH, Frichione SR, Edwards SM, de la Monte SM, Swift RM et al. Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiatry 2014; 76: 734–741.
11 Hillenmacher T, Bleich S, Freiling H, Scharanze A, Wilhelm J, Sperling W et al. Evidence of an association of leptin serum levels and craving in alcohol dependence. Psychoneuroendocrinology 2007; 32: 87–90.
12 Kiefer F, Jahn H, Jaschinski M, Holzbach R, Wolf K, Naber D et al. Leptin: a modulator of alcohol craving? Biol Psychiatry 2001; 49: 782–787.
13 Kiefer F, Jahn H, Otte C, Demiralay C, Wolf K, Wiedemann K. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism. J Psychiatr Res 2005; 39: 545–551.
14 Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199–2202.
15 Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426–430.
16 Al-Suhaime EA, Shehzad A, Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res 2013; 18: 12.
17 Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiophysical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511–1526.
18 Elmquist JK, Maratos-Flier E, Saper CB, Flier JS. Unraveling the central nervous system–leptin cross-talk in alcoholism and that their increase in alcohol dependence—possible link to craving. Drug Alcohol Depend 2009; 99: 333–337.
19 Traebert M, Riediger T, Whitebread S, Scharrer E, Schmidt HA. Ghrelin acts on leptin-responsive neurons in the rat arcuate nucleus. J Neuroendocrinol 2002; 14: 580–586.
20 Dieguez C, Vazquez MJ, Romero A, Lopez M, Nogueiras R. Hypothalamic control of lipid metabolism: focus on leptin, ghrelin and melanocortins. Neuroendoocrinology 2011; 94: 1–11.
21 Figlewicz DP, Evans SB, Murphy J, Hoen M, Baskin DG. Expression of receptors for ghrelin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 2003; 964: 107–115.
22 Egicioglu E, Jerlhag E, Salome N, Skibicka KP, Haagde, Bohlhooy-L et al. Increased levels of adiponectin and resistin in alcohol dependence—possible link to craving. Addict Biol 2010; 15: 304–311.
23 Bonci A, Bernardi G, Grillner P, Mercuri NB. The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci 2003; 24: 172–177.
24 Braus DF, Wrase J, Grussner S, Hermann D, Ruf M, Flor H et al. Alcohol-associated stimuli activate the ventral striatum in abstinent alcoholics. J Neural Transm 2001; 108: 887–894.
25 Gross PM. Circumventricular organ capillaries. Prog Brain Res 1992; 91: 219–233.
26 Robsenow DJ, Monti PM, Hutchinson KE, Swift RM, Colby SM, Kaplan GB. Naltrexone’s effect on reactivity to alcohol cues among alcoholic men. J Abnorm Psychol 2000; 109: 738–742.
27 Paulo RC, Brundage R, Cosma M, Mielel KL, Bowers CY, Veldhuis JD. Estrogen elevates the peak overnight production rate of acylated ghrelin. J Clin Endocrinol Metab 2008; 93: 4440–4447.
28 Monti PM, Roschenow DJ, Hutchinson KE, Swift RM, Mueller TI, Colby SM et al. Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 1999; 23: 1386–1394.
29 Sloan C, Tuinei J, Nemetz K, Frandsen J, Soto J, Wride N et al. Central leptin signaling is required to normalize myocellular fatty acid oxidation rates in calorically restricted ob/ob mice. Diabetes 2011; 60: 1424–1434.
30 Hellstrom L, Wahrenberg H, Hruska K, Reynisdottir S, Arner P. Mechanisms behind gender differences in circulating leptin levels. J Intern Med 2000; 247: 457–462.
31 Tabachnick BG, Fidel LS. Using Multivariate Statistics, 3rd edn. HarperCollins: New York. 1996.
32 Evangelopoulos ME, Koutis G, Markianos M. Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis. Autoimmune Dis 2014; 2014: 486282.
33 Leggio L. Understanding and treating alcohol craving and dependence: recent pharmacological and neuroendocrinological findings. Alcohol Alcohol 2009; 44: 341–352.
34 Ray LA, Hutchinson KE, Tarter M. Application of human laboratory models to pharmacotherapy development for alcohol dependence. Curr Pharm Des 2010; 16: 2149–2158.
35 Schwartz MW, Woods SC, Porte Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661–671.
37 Cummings DE, Foster KE. Ghrelin–leptin tango in body-weight regulation. Gastroenterology 2003; 124: 1532–1535.
38 Schmid DA, Held K, Ising M, Uhr M, Weikel JC, Steiger A. Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but does not affect leptin in normal controls. Neuropsychopharmacology 2003; 30: 1187–1192.
39 Oomura Y, Hori N, Shiraishi T, Fukunaga K, Takeda H, Tsuji M et al. Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 2006; 27: 2738–2749.
40 Deng ZH, Liao J, Zhang JY, Liang C, Song CH, Han M et al. Inhibition of the connexin 43 elevation may be involved in the neuroprotective activity of leptin against brain ischemic injury. Cell Mol Neurobiol 2014; 34: 871–879.
41 Kim MS, Namkoong C, Kim HS, Jang PG, Kim Pak YM, Katakami H et al. Chronic central administration of ghrelin reverses the effects of leptin. Int J Obes Relat Metab Disord 2004; 28: 1264–1271.
42 Kim JH, Kim SJ, Lee WY, Cheon YH, Lee SS, Ju A et al. The effects of alcohol abstinence on BDNF, ghrelin, and leptin secretions in alcohol-dependent patients with glucose intolerance. Alcohol Clin Exp Res 2013; 37(Suppl 1): E52–E58.
43 Leinninger GM, Jo YH, Leshan RL, Louis GW, Yang H, Barrera JG et al. Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding. Cell Metab 2009; 10: 89–98.
44 Fruhbeck G, Gomez-Ambrosio J, Martinez JA. Pre- and postprandial expression of the leptin receptor splice variants OB-Ra and OB-Rb in murine peripheral tissues. Physiol Res 1999; 48: 189–195.
45 Anubhuti, Arora S. Leptin and its metabolic interactions: an update. Diab Obes Metab 2008; 10: 973–993.
46 Perello M, Scott MM, Sakata I, Lee CE, Chuang JC, Osborne-Lawrence S et al. Functional implications of limited leptin receptor and ghrelin receptor coexpression in the brain. J Comp Neurol 2012; 520: 281–294.
47 Giovambattista A, Piermaria J, Suescun MO, Calandra RS, Gaillard RC, Spinedi E. Direct effect of ghrelin on leptin production by cultured rat white adipocytes. Obesity 2006; 14: 19–27.
48 Choi K, Roh SG, Hong YH, Shrestha YB, Hishikawa D, Chen C et al. The role of ghrelin and growth hormone secretagogues receptor on fat adipogenesis. Endocrinology 2003; 144: 754–759.
49 Shintani M, Ogawa Y, Ebihara K, Aizawa-Abé M, Miyanaga F, Takaya K et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50: 227–232.
50 Speakman JR, Stubbs RJ, Mercer JC. Does body mass play a role in the regulation of food intake? Proc Nutr Soc 2002; 61: 473–487.
51 Monti V, Carlson JJ, Hunt SC, Adams TD. Relationship of ghrelin and leptin hormones with body mass index and waist circumference in a random sample of adults. J Am Diet Assoc 2006; 106: 822–828.
52 Hotamisligil GS. The irresistible biology of resistin. J Clin Invest 2003; 111: 173–174.
53 Nohira T, Nagao K, Kamesaya K, Nakai H, Fukumine N, Okabe K et al. Identification of an alternative splicing transcript for the resistin gene and distribution of its mRNA in human tissue. Eur J Endocrinol 2004; 151: 151–154.
54 Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007; 92: 666–672.
55 Garin MC, Burns CM, Kaul S, Cappola AR. Clinical review: The human experience with ghrelin administration. J Clin Endocrinol Metab 2013; 98: 1826–1837.
56 Kenna GA, Swift RM, Hillemacher T, Leggio L. The relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humans. Neuropsychol Rev 2012; 22: 211–228.
57 Monti PM, Binkoff JA, Abrams DB, Zwick WR, Nirenberg TD, Liepmann MR. Reactivity of alcoholics and nonalcoholics to drinking cues. J Abnorm Psychol 1987; 96: 122–126.